Latest Biotech News

Slate Medicines announced a reverse merger with Fulcrum Therapeutics and a $245 million financing to build out a migraine pipeline after Fulcrum exited its sickle cell program. The combined plan...

Eyepoint’s Phase 3 program for Duravyu (vorolanib intravitreal insert) missed its primary goal, failing to show sustained vision maintenance with less frequent injections versus standard dosing....

Argenx reported late-stage Phase 3 top-line results for Vyvgart Hytrulo (subcutaneous efgartigimod alfa) in autoimmune myositis, with statistical significance in a combined study that included...

A JAMA-published adaptive clinical trial from University of Pittsburgh physician-scientists found refrigerated, chilled platelets can remain effective for up to 21 days, expanding the available...

AstraZeneca ended a Phase 3 trial of volrustomig after an interim data check indicated it was unlikely to meet survival endpoints when combined with chemotherapy. The decision adds to a series of...

A U.S. court cleared the path for a trustee suit alleging Bristol Myers Squibb delayed FDA approval of Breyanzi, a gene therapy for non-Hodgkin lymphoma, to avoid milestone payments tied to its...

Integrated DNA Technologies (IDT) introduced a workflow aimed at improving CRISPR off-target site nomination, using UNCOVERseq to streamline the jump from high-throughput discovery to targeted...

Tagomics is aiming to improve drug safety monitoring with a new cell-free DNA blood test built on its LiquiPath platform. The company’s approach uses tagging and enrichment of unmethylated genomic...

Early testing suggests gene-edited beagles produce no detectable major dog allergen, Can f 1, addressing a key driver of dog allergy symptoms. The result, based on preliminary assessments, targets...

Fresenius announced a €200 million corporate venture capital fund to back emerging biotech talent through its Fresenius Ventures program over the next five years. The structure is designed to...

Argenx reported positive late-stage results for Vyvgart Hytrulo (subcutaneous efgartigimod) in a Phase 3 program across adults with myositis, aiming to broaden use of the Vyvgart franchise. The...

AstraZeneca halted a Phase 3 lung cancer study of volrustomig after an interim data review suggested survival goals were likely to be missed. The discontinuation follows a broader pattern of...

EyePoint reported unfavorable pivotal Phase 3 results for its experimental therapy in wet age-related macular degeneration (wet AMD), undermining the case for approval against the current standard...

Researchers described a portfolio-wide standardized clinical trial subject ID schema designed to solve CRO and sponsor tracking problems caused by study-specific identifier conventions. The paper...

The Jackson Laboratory highlighted how next-generation immuno-oncology modeling platforms aim to better reflect the tumor microenvironment for therapy development. The focus is on improving...

A new tumor-derived organoid biobank created and publicly characterized 256 clinically annotated organoid models spanning colorectal, oesophageal, ovarian, pancreatic, and gastric cancers, paired...

Researchers reported a virus-like particle approach designed to improve gene engineering and enable pooled CRISPR screening in primary human myeloid cells, including monocytes, macrophages, and...

Celcuity disclosed that it is awaiting FDA review for a second manufacturing site after the company’s recently approved cancer drug’s commercial rollout progressed more slowly than investors...

Slate Medicines agreed to combine with Fulcrum Therapeutics in a reverse merger, aiming to move toward a Nasdaq listing while financing migraine development. The deal follows Fulcrum’s earlier...

Jefferies and BTIG initiated coverage of Freenome with buy ratings, citing the scale of the addressable market for its cancer screening approach and pointing to commercialization partnerships. The...